Preventive effect of high-fluoride dentifrice (5,000 ppm) in caries-active adolescents: a 2-year clinical trial.
There is a lack of clinical studies comparing dentifrices with high fluoride (F) concentration. The aim was to evaluate a dentifrice containing 5,000 ppm F compared to a dentifrice containing 1,450 ppm F in caries-active adolescents. The design was a 2-year, single-blind randomized controlled trial and 211 adolescents of 279 (76%) completed the trial. The subjects were divided into two groups and were given one of the assigned F dentifrices for daily unsupervised toothbrushing: (1) Duraphat 5,000 ppm F and (2) Pepsodent Superfluor 1,450 ppm F, both as NaF. The outcome variables were caries incidence and progression of proximal and occlusal caries. The subjects were asked to fill in a questionnaire to evaluate their compliance and they were divided into two subgroups: subgroup A, excellent compliance, and subgroup B, poor compliance. The latter group (28%) comprised the subjects who did not brush twice a day or did not use the dentifrice regularly. Adolescents using 5,000 ppm F toothpaste had significantly lower progression of caries compared to those using 1,450 ppm F toothpaste (A: p < 0.01, B: p < 0.001), with a prevented fraction of 40%. Subjects using 5,000 ppm F toothpaste had significantly lower caries incidence for compliance B compared to those using 1,450 ppm F toothpaste (p < 0.05); the prevented fraction was 42%. This may indicate that 5,000 ppm F toothpaste has a greater impact on individuals who do not use toothpaste regularly or do not brush twice a day. Thus, 5,000 ppm F toothpaste appears to be an important vehicle for caries prevention and treatment of adolescents with a high caries risk.
Nordström
A
A
Department of Cariology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Birkhed
D
D
D000293:Adolescent; D000367:Age Factors; D004245:DMF Index; D003731:Dental Caries / Q000000981:diagnostic imaging / Q000517:prevention & control*; D003802:Dentifrices / Q000008:administration & dosage* / Q000627:therapeutic use; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D005460:Fluorides, Topical / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010349:Patient Compliance; D016300:Radiography, Bitewing; D012307:Risk Factors; D012737:Sex Factors; D016037:Single-Blind Method; D012969:Sodium Fluoride / Q000008:administration & dosage* / Q000627:therapeutic use
D003802:Dentifrices; D005460:Fluorides, Topical; C542316:pepsodent superfluor; C023807:sodium fluoride topical preparation; D012969:Sodium Fluoride